Results 21 to 30 of about 4,590 (196)
Journal of Pharmacology and Pharmacotherapeutics, 2012 Insulin glargine is a long acting novel recombinant human insulin analogue indicated to improve glycemic control, in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. The time course of action of insulins including insulin glargine may vary between individuals and/or within the same individual.
Ozlem Guneysel +3 more
openaire +3 more sources
On the safety of insulin Glargine
Diabetes mellitus, 2009 Последние дни мировая медицинская общественность обсуждает публикации в журнале диабетология?, посвященные анализу безопасности применения инсулина гларгин, проведенному в Германии, Швеции, Шотландии и Великобритании на основании данных регистров больных сахарным диабетом этих стран.
Marina Vladimirovna Shestakova +2 more
openaire +3 more sources
Cardiovascular Diabetology, 2008 Objective Exenatide belongs to a new therapeutic class in the treatment of diabetes (incretin mimetics), allowing glucose-dependent glycaemic control in Type 2 diabetes.
Tetlow Anthony P +3 more
doaj +1 more source
Special aspects of concentrated insulins: basic characteristics and research findings
Сахарный диабет, 2019 The appearance of concentrated insulins in clinical practice determines the need to analyze product priorities in appropriate groups of patients with diabetes. The aim of this article is to summarize the literature on concentrated insulins (i.e.
Tatiana Y. Demidova, Olga V. Balutina
doaj +1 more source
Evaluation of the innate immunostimulatory potential of originator and non-originator copies of insulin glargine in an in vitro human immune model. [PDF]
PLoS ONE, 2018 BackgroundThe manufacture of insulin analogs requires sophisticated production procedures which can lead to differences in the structure, purity, and/or other physiochemical properties of resultant products that can affect their biologic activity.
Ernesto Luna +10 more
doaj +1 more source
Security, extensibility, and redundancy in the Metabolic Operating System [PDF]
arXiv, 2023 People living with Type 1 Diabetes (T1D) lose the ability to produce insulin naturally. To compensate, they inject synthetic insulin. One common way to inject insulin is through automated insulin delivery systems, which use sensors to monitor their metabolic state and an insulin pump device to adjust insulin to adapt.
arxiv
Frontiers in Endocrinology, 2019 Our aim was to investigate whether human insulin (HI) or insulin glargine treatment could promote the proliferation of thyroid cells and determine the association between type 2 diabetes and thyroid disease.
Xiaoli Sheng +6 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Insulin glargine is a long-acting insulin analog, which plays an important role in the treatment of diabetes mellitus. Biosimilar products of insulin glargine can provide patients with additional safe, high-quality, and potentially cost-effective options
Yiya Wang +7 more
doaj +1 more source
Effects of glargine on hyperglycemia in patients with diabetes mellitus type II undergoing off-pump coronary artery bypass graft: A randomized, controlled, double-blind clinical trial [PDF]
Journal of Cardiovascular and Thoracic Research, 2023 Introduction: In this trial, effects of glargine on hyperglycemia in patients with diabetes mellitus type II who were undergoing off-pump coronary artery bypass graft (CAGB), were examined.
Shima Sheybani +5 more
doaj +1 more source
Comparative Analysis of Kinetic Realizations of Insulin Signaling [PDF]
arXiv, 2023 Several studies have developed dynamical models to understand the underlying mechanisms of insulin signaling, a signaling cascade that leads to the translocation of glucose, the human body's main source of energy. Fortunately, reaction network analysis allows us to extract properties of dynamical systems without depending on their model parameter ...
arxiv